top of page

The Leadership Team

Our Team

1.jpeg
1.jpeg

Matt Landry

CBO, Pre-Clinical Lead

Matthew Landry, BS, is a seasoned Life Sciences Executive with over 20 years of expertise spanning the biotechnology, pharmaceutical, and diagnostic sectors. Previously serving as Vice President of Reagents and Consumables at Scientist.com, Matthew led the development of a product division encompassing over 1,000 suppliers and successfully negotiated 500+ agreements with suppliers, demonstrating his adeptness at fostering advantageous partnerships.

As Vice President of Marketing and Sales at Aviva Systems Biology, he successfully integrated GenWay Biotech post-acquisition and launched innovative biomarker and antibody solutions, driving exponential revenue growth. His domain expertise extends across recombinant antibody development, ELISA, immunohistochemistry, lateral flow assays, multiplexing technologies, and biochemical analysis. A recognized Subject Matter Expert (SME) in proteomics, Matthew has developed strategic roadmaps that contributed to securing 10,000+ new customers and achieving a six-fold increase in revenue.

Matthew is deeply experienced in regulatory compliance, market trend analysis, and building research collaborations to support clinical and preclinical innovation. He holds a Bachelor of Science in Biotechnology and Microbiology from the University of California, Davis, and is a published author with contributions in scientific and industry-leading publications.

858-945-6281

  • LinkedIn

Sergey Sikora, PhD, MBA

CEO, Clinical Lead

Sergey Sikora, MBA, PhD is a Strategic and Clinical Consultant, specializing in providing strategic, M&A, transactions, and clinical development support to pharmaceutical and biopharmaceutical start-ups to mid-size companies and traditional biotechnology and pharmaceutical venture capital firms. He left Releviate Therapeutics in the mid-2024 (company developing non-addictive, antibody-based, disease-modifying neuropathic pain therapy) as the Chief Executive Officer and a Member of the Board of Directors. Sergey's 20 years of experience in the biotechnology industry spans the spectrum of pharmaceutical, biopharmaceutical, and diagnostic industries. Before Releviate, Sergey founded and managed CardioCell, cell therapy company focusing on cardiovascular diseases. During his tenure at CardioCell he took the company from inception to Phase III. Sergey's expertise spans cardiovascular, neurodegenerative, neuropathic pain, ophthalmology, dermatology, autoimmune, rheumatology, and rare diseases, such as Duchenne's muscular dystrophy, ALS. During his tenure as the CEO of CardioCell he served on the FDA discussion panel for heart failure, along with top KOLs in heart failure and heart failure industry leaders from AstraZeneca and Bayer, resulting in the position paper. Sergey is also recognized as Top 20 Most Notable UCSD Alumni in the Business World, according to the Money, Inc. Sergey earned a B.S. in Biochemistry at UCLA, a Ph.D. in Molecular Biology from UCLA , and an M.B.A from the Rady School of Management, UCSD. He has multiple patents and multiple clinical peer-reviewed publications.

760-315-0861

  • LinkedIn
IMG_1313.JPG
bottom of page